Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Imunon

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1982-01-01

Employees: 33

Market Cap: $16.7M

Website: http://imunon.com

Clinical Trials

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Phase 3

Recruiting

Conditions: Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
Ovarian Cancer
Fallopian Tube Cancer

Interventions: Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Drug: Paclitaxel
Drug: Carboplatin
Drug: Olaparib
Drug: Niraparib

First Posted Date: 2025-04-07

Last Posted Date: 2025-07-08

Lead Sponsor: Imunon

Target Recruit Count: 500

Registration Number: NCT06915025

Locations: 🇺🇸
Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
🇺🇸
Providence Cancer Institute, Portland, Oregon, United States
🇺🇸
Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington, United States

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Phase 1

Active, not recruiting

Conditions: SARS CoV 2 Infection

Interventions: Biological: IMNN-101

First Posted Date: 2024-02-28

Last Posted Date: 2025-06-05

Lead Sponsor: Imunon

Target Recruit Count: 74

Registration Number: NCT06283459

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
DM Clinical Research, Philadelphia, Pennsylvania, United States

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab
Drug: IMNN-001

First Posted Date: 2023-02-22

Last Posted Date: 2025-07-03

Lead Sponsor: Imunon

Target Recruit Count: 50

Registration Number: NCT05739981

Locations: 🇺🇸
Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Phase 1

Active, not recruiting

Conditions: Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Fallopian Tube Cancer

Interventions: Biological: IMNN-001
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2018-01-09

Last Posted Date: 2025-07-03

Lead Sponsor: Imunon

Target Recruit Count: 130

Registration Number: NCT03393884

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Mitchell Cancer Institute (University of South Alabama), Mobile, Alabama, United States
🇺🇸
Gynecologic Oncology Associates (Hoag Hospital), Newport Beach, California, United States

and more 18 locations

Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: ThermoDox (Thermally Sensitive Liposomal Doxorubicin)
Radiation: Radiation Therapy
Device: Superficial Hyperthermia

First Posted Date: 2016-08-01

Last Posted Date: 2022-04-07

Lead Sponsor: Imunon

Registration Number: NCT02850419

Locations: 🇨🇿
Inst. of Radiation Oncology Hospital Na Bulovce, Prague, Czechia
🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇹
Fondazione Del Piemonte Per L'Oncologia - Irccs Candiolo, Candiolo, Italy

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Phase 1

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Biological: IMNN-001

First Posted Date: 2015-06-24

Last Posted Date: 2024-10-02

Lead Sponsor: Imunon

Target Recruit Count: 18

Registration Number: NCT02480374

Locations: 🇺🇸
University of Alabama Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Washington Univ. in St. Louis/Barnes Jewish Hospital, St. Louis, Missouri, United States
🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

and more 1 locations

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: ThermoDox
Drug: Dummy infusion

First Posted Date: 2014-04-14

Last Posted Date: 2024-08-20

Lead Sponsor: Imunon

Target Recruit Count: 554

Registration Number: NCT02112656

Locations: 🇺🇸
UCLA Department of Medicine, Los Angeles, California, United States
🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇨🇳
Mengchao Hepatobiliary Hospital of Fujian Medicatl University, Fuzhou, Fujian, China

and more 58 locations

MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases

Phase 2

Withdrawn

Conditions: Small Cell Lung Cancer
Painful Bone Metastases
Breast Carcinoma
Non-small Cell Lung Cancer
Adenocarcinoma

Interventions: Drug: High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox

First Posted Date: 2012-07-16

Last Posted Date: 2017-02-07

Lead Sponsor: Imunon

Registration Number: NCT01640847

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

Phase 2

Terminated

Conditions: Colon Cancer Liver Metastasis

Interventions: Drug: Lyso-Thermosensitive Liposomal Doxorubicin
Other: 5% Dextrose Solution
Drug: ThermoDox

First Posted Date: 2011-11-03

Last Posted Date: 2022-10-13

Lead Sponsor: Imunon

Target Recruit Count: 2

Registration Number: NCT01464593

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸
Cleveland Clinic Hospital, Cleveland, Ohio, United States

and more 1 locations

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: ThermoDox in combination with Microwave Hyperthermia (heat)

First Posted Date: 2009-01-21

Last Posted Date: 2017-01-30

Lead Sponsor: Imunon

Target Recruit Count: 17

Registration Number: NCT00826085

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Southeastern Regional Medical Center, Newnan, Georgia, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy